AI Automated Translation.

Font Size

Share

Celltrion Wins Brazil Federal Government Bid for Hercepta for 7th Consecutive Year… "Overwhelming Dominance"

Celltrion Wins Brazil Federal Government Bid for Hercepta for 7th Consecutive Year… "Overwhelming Dominance"

Celltrion's breast and gastric cancer treatment 'Hercepta' (generic name: trastuzumab). /Photo=Provided by Celltrion
Celltrion's breast and gastric cancer treatment 'Hercepta' (generic name: trastuzumab). /Photo=Provided by Celltrion

Celltrion announced on the 17th that its breast and gastric cancer treatment 'Hercepta' (generic name: trastuzumab) has successfully won a federal government bid in Brazil, the largest pharmaceutical market in Latin America. Since securing its first contract in 2020, the year following its launch, Hercepta has been awarded the Brazilian federal government bid for seven consecutive years through this year.

With this win, Celltrion's Brazilian subsidiary will exclusively supply approximately 1 million vials of Hercepta by the end of next year. Notably, this bid accounts for approximately 80% of Brazil's public market for trastuzumab. As a result, Celltrion can secure both a solid market position and a stable sales foundation in Brazil.

Brazil's pharmaceutical market is broadly divided into the public market, which is under federal government jurisdiction, and the private market, where hospitals independently select products. The ratio of the public to private markets is approximately 8:2. Celltrion's Brazilian subsidiary has strengthened its position by consistently achieving contract results in the public market, a key channel, based on a customized direct sales strategy tailored to local market characteristics and product competitiveness.

Celltrion's Brazilian subsidiary has focused on building networks with key stakeholders related to the federal government while steadily expanding contact points with core medical professionals. In Brazil, it is common for major medical professionals to work simultaneously in both public and private healthcare institutions. The company plans to leverage the product trust and brand preference accumulated in the public market to expand into the private market, aiming for additional growth of Hercepta.

Celltrion's stable pharmaceutical supply capabilities are also cited as a key competitive advantage that drove this win. Few companies possess a stable global bio-pharmaceutical supply infrastructure. Celltrion holds production competitiveness capable of supplying 1 million vials to a single country without disruption. Analysts say this supply stability worked positively in the federal government bid as well.

Hercepta currently maintains the top prescription ranking in Brazil with an approximately 50% market share (IQVIA), surpassing the original and competing products.

Recently, Celltrion expanded its product portfolio to 10 items by launching autoimmune disease treatment 'Coivolma' (generic name: ustekinumab) and bone disease treatments 'Stoboclo·Ocenbelt' (generic name: denosumab) in Brazil. Its flagship product, the autoimmune disease treatment 'Remsima' (generic name: infliximab), records an approximately 50% share in the Brazilian private market.

Celltrion's strategy is to strengthen growth drivers in Brazil through expanded prescriptions of existing products and the launch of new product lines. The company plans to expand the supply of chronic spontaneous urticaria treatment 'Omriclo' (generic name: omalizumab), ophthalmic disease treatment 'Idengelt' (generic name: aflibercept), and autoimmune disease treatment 'Aptozma' (generic name: tocilizumab).

Kang Kyung-du, Celltrion's regional director for Latin America, said, "The long-term results in Brazil are the outcome of an organic synergy between a sales strategy optimized for the local market, a robust network, and high product trust." He added, "By adding follow-up product lines to the direct sales competitiveness built through existing products, we will expand our market influence in Brazil and use this as a springboard to continuously create new growth opportunities across Latin America."

"This article was translated using AI and may differ slightly from the original."